AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and Rinvoq.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

DelveInsight's 'Endometriosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometriosis ...

Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th 5.25% Cum. Redeem. Pfd. Series M) 1.41% Kimco Realty Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Cl L) 1.09% Federal Realty Investment Trust Dep. Pfd. (Rep. 1 ...

Approximately 10% of women of reproductive age worldwide are affected by endometriosis, equating to about 190 million individuals. This substantial patient population necessitates effective ...

That brand is more than just a logo - it’s your company’s reputation. It’s what people remember about your business when a buying decision arises, and any product under that brand umbrella ...

Merck & Co. Inc. 2.50% $241.71B ...